LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and AI solutions for Latin America, announced on August 3, 2026, that it has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory workflows. The collaboration, conducted through LataMed AI's Venezuelan subsidiary LATAMEDAI VE, aims to design, develop, test, and evaluate customized technology to support pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to include software tools that organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may encompass workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools designed to help qualified personnel identify potential inconsistencies or operational issues earlier. The parties will begin by identifying specific workflows, defining technical and operational requirements, and establishing a phased development and testing process. They also intend to set up confidentiality, information-security, data-management, and access-control procedures.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The collaboration could expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications, complementing its patient-facing telemedicine services. It aligns with the company's broader strategy of developing digital infrastructure and AI tools for healthcare providers, pharmacies, laboratories, institutions, and other ecosystem participants. If successfully developed, the technology might provide a framework adaptable for other organizations in Venezuela and Latin America, though any expansion would depend on separate agreements, successful testing, operational readiness, and regulatory compliance.
The agreement also outlines that the parties will evaluate ownership, licensing, permitted use, and protection of any intellectual property developed. However, it does not guarantee a specific implementation schedule, commercial deployment, cost reductions, or revenue. The technology is intended as a decision-support and workflow-management resource and will not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All professional judgments remain with qualified scientists, pharmacists, laboratory personnel, healthcare providers, and regulatory authorities.
This initiative underscores the growing role of AI in pharmaceutical and laboratory settings, potentially improving efficiency and accuracy while maintaining human oversight. For LataMed AI, it represents a strategic step toward diversifying its offerings and establishing a presence in the enterprise healthcare technology market. The partnership with DROGUERIAS LALA C.A., a Venezuelan pharmaceutical distributor, could pave the way for broader adoption of AI-driven tools in the region's healthcare infrastructure.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
